Curis Competitors

Curis (NASDAQ:CRIS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares Curis and Amgen's gross revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Curis has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Curis and Amgen, as provided by MarketBeat.com.

Curis presently has a consensus price target of $12.00, indicating a potential upside of 31.43%. Amgen has a consensus price target of $257.3043, indicating a potential upside of 15.95%. Given Curis' stronger consensus rating and higher probable upside, research analysts plainly believe Curis is more favorable than Amgen.

Insider & Institutional Ownership

34.7% of Curis shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 7.3% of Curis shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Curis and Amgen's net margins, return on equity and return on assets.

Summary

Amgen beats Curis on 9 of the 14 factors compared between the two stocks.

Curis (NASDAQ:CRIS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

34.7% of Curis shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 7.3% of Curis shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Curis and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Curis has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Curis and Gilead Sciences, as provided by MarketBeat.com.

Curis presently has a consensus price target of $12.00, indicating a potential upside of 31.43%. Gilead Sciences has a consensus price target of $96.0370, indicating a potential upside of 51.89%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Curis.

Profitability

This table compares Curis and Gilead Sciences' net margins, return on equity and return on assets.

Summary

Gilead Sciences beats Curis on 10 of the 14 factors compared between the two stocks.

Curis (NASDAQ:CRIS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares Curis and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

34.7% of Curis shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 7.3% of Curis shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Curis has a beta of 3.29, indicating that its stock price is 229% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Curis and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Curis and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Curis presently has a consensus price target of $12.00, suggesting a potential upside of 31.43%. Vertex Pharmaceuticals has a consensus price target of $292.68, suggesting a potential upside of 40.85%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Curis.

Summary

Vertex Pharmaceuticals beats Curis on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Curis (NASDAQ:CRIS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Regeneron Pharmaceuticals and Curis, as provided by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus target price of $625.8077, suggesting a potential upside of 39.26%. Curis has a consensus target price of $12.00, suggesting a potential upside of 31.43%. Given Regeneron Pharmaceuticals' higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Curis.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Curis' revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.29, meaning that its share price is 229% more volatile than the S&P 500.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 34.7% of Curis shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of Curis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Curis' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Curis on 12 of the 15 factors compared between the two stocks.

Curis (NASDAQ:CRIS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Curis and Biogen, as provided by MarketBeat.com.

Curis currently has a consensus target price of $12.00, suggesting a potential upside of 31.43%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 15.52%. Given Curis' stronger consensus rating and higher probable upside, equities analysts plainly believe Curis is more favorable than Biogen.

Valuation and Earnings

This table compares Curis and Biogen's revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Curis and Biogen's net margins, return on equity and return on assets.

Volatility and Risk

Curis has a beta of 3.29, suggesting that its share price is 229% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Insider & Institutional Ownership

34.7% of Curis shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 7.3% of Curis shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Biogen beats Curis on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Curis (NASDAQ:CRIS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Alexion Pharmaceuticals and Curis, as reported by MarketBeat.com.

Alexion Pharmaceuticals presently has a consensus price target of $153.1250, suggesting a potential upside of 3.14%. Curis has a consensus price target of $12.00, suggesting a potential upside of 31.43%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Alexion Pharmaceuticals.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Curis' top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Curis' net margins, return on equity and return on assets.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.29, indicating that its stock price is 229% more volatile than the S&P 500.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 34.7% of Curis shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Curis on 10 of the 15 factors compared between the two stocks.